REGN Trading Analysis - 10/23/2026 02:23 PM — TRU-SENTIMENT

News Headlines & Context

Recent general knowledge headlines and context for Regeneron Pharmaceuticals (REGN):

• Regeneron's Eylea HD continue to gain market share in ophthalmology, supporting revenue stability into late 2026.
• Earlier in 2026, concerns over Medicare drug price negotiations for Dupixent created periodic pressure on sentiment.
• REGN presented positive mid-stage data for a next-gen anti-inflammatory asset at a major medical conference in Q3 2026.
• No confirmed near-term earnings date in this context, but fiscal year end was 2025-12-01 per fundamentals.
• Low beta (0.06) suggests REGN has been largely insulated from broad market volatility per provided fundamentals.

Context: These fundamental and pipeline narratives contrast with the embedded data showing a sharp October price recovery and bullish options flow, though technicals hint at overextension (RSI 80.60).

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for REGN:

• Trailing P/E is 19.30 with trailing EPS of $41.88; valuation appears moderate versus typical large-cap biotech peers.
• Market cap is $84,373,166,825.00 with shares outstanding of 102,955,000.00.
• Dividend yield is 0.47% (rate $3.76), ex-dividend 2026-08-18 — minor income component.
• Beta is 0.06 indicating very low correlation to broad market moves.
• 52-week range: low $572.75, high $859.34; current price $819.52 is near the upper third.
• Institutional ownership is 63.71% — moderate institutional base.
• Historical volatility is 28.80%; average volume 692,000.00.
• PEG, forward P/E, P/B, revenue growth, margins, ROE, D/E, FCF, analyst target all null — no growth/margin quality data available.

Fundamentals show stable earnings and low beta, but absent margin and growth metrics create a divergence from the strong technical rebound and bullish options sentiment observed in the data.

Current Market Position

Current price from indicators: $819.52. Daily history shows 2026-10-22 close at $819.52 (high $825.52, low $800.00, volume 622,331). Minute bars for 2026-10-21 opened $806.74 and closed near $806.63 first bar; last 2026-10-22 15:55 bar closed $819.33 after dipping to $818.89. Intraday momentum on 10-22 was positive with late-session volume spike (48,431) holding above $818.00.

Technical Analysis

SMA alignment: 5-day ($800.61) > 50-day ($791.24) > 20-day ($765.02) with price $819.52 above all — bullish structure but 20-day lags. RSI 80.60 indicates overbought. MACD histogram +1.45 (bullish). Bollinger upper $820.51; price at $819.52 is at band edge (expansion). 30-day range high $825.52, low $722.02 — price in top 2.6% of range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only) shows Bullish sentiment:

Call Volume: $686,260.00 (63.80%) Put Volume: $389,740.00 (36.20%) Total: $1,076,000.00

• 114 call contracts vs 55 put contracts; 19 call trades vs 5 put trades.
• Pure directional conviction leans bullish into 2026-11-20 expiration.
• Divergence: option spread engine flagged "Divergence detected between technical indicators and options sentiment" — technicals overbought vs bullish flow.

Key Price Levels (Observational Only)